Weekly Digest

FDA Warns Consumers Not to Use Addall XR Shot or Addall XL Capsules Sold at Gas Stations

U.S. Food and Drug Administration • April 2026

The FDA issued a safety advisory urging consumers, retailers, and distributors to avoid Addall XR Shot and Addall XL Capsules, both distributed by ZMB Enterprises of Carlsbad, California. Testing found both products contain undeclared 1,4-DMAA, a stimulant not lawfully permitted in supplements; the shot also contains phenibut, which can cause addiction and serious neurocognitive side effects. ZMB agreed to a limited voluntary recall of only the shot, declining to pull the capsules, prompting the FDA to issue this direct advisory calling on retailers to remove both products from shelves immediately.

FDA Closes Salmonella Investigation Linked to Moringa Supplement Capsules

Food Safety News • April 2026

The FDA officially closed its investigation into a Salmonella outbreak linked to Rosabella-brand moringa powder capsules distributed by Ambrosia Brands LLC. Ten patients across eight states were confirmed ill, with three hospitalizations; the outbreak strain was extensively drug-resistant, raising broader questions about antimicrobial resistance in the supplement supply chain. Preventive screening of imported moringa is continuing even as the root cause of contamination remains unidentified, underscoring the gap between DSHEA’s intent and the practical limits of post-market enforcement.

Kian Pee Wan Capsules Recalled After FDA Finds Undeclared Prescription Drug Ingredients

U.S. Food and Drug Administration • April 2, 2026

Kian Pee Wan Capsules were recalled on April 2, 2026, after FDA testing found the product contained undeclared dexamethasone and cyproheptadine, both prescription-only drugs not permitted in dietary supplements. The incident continues a documented pattern of adulterated supplement products reaching consumers and highlights the gap between DSHEA’s requirement that manufacturers ensure safety before marketing and the enforcement reality in which adulteration is discovered only after market entry.

SANS 2026: State Supplement Laws and Class Action Surge Create New Compliance Pressure

NutraIngredients • April 1, 2026

The 2026 Supplements and Natural Solutions conference revealed a growing legal landscape threatening supplement brands from two directions: a patchwork of state regulations that often exceed federal DSHEA standards, and a rising wave of class action lawsuits targeting claims around flavor designations, protein content, and natural ingredient characterizations. California and New York continue to drive the bulk of supplement litigation, and industry advocates are calling on Congress to advance the Dietary Supplement Regulatory Uniformity Act to establish a single, science-based national standard and protect brands against state-level overreach.

Herbalife Acquires Cristiano Ronaldo-Backed Bioniq in $150 Million Personalized Nutrition Deal

NutraIngredients • March 30, 2026

Herbalife announced a planned acquisition of assets from Bioniq, a London-based personalized supplement firm, in a deal worth up to $150 million. Bioniq, which counts soccer star Cristiano Ronaldo among its equity investors, creates individualized supplement formulas based on blood work and health data for hundreds of thousands of users across more than 40 countries. The deal reflects a sector-wide shift toward technology-enabled, data-driven wellness platforms, with implications for how DSHEA-governed products are formulated, labeled, and marketed to increasingly health-literate consumers.

FDA Approves First Oral GLP-1 Drug, Expanding the Supplement Companion Market

OneDayMD • April 1, 2026

The FDA’s April 1 approval of Eli Lilly’s orforglipron (Foundayo), the first oral GLP-1 receptor agonist for obesity and type 2 diabetes priced at $149 per month, is expected to dramatically expand the pool of GLP-1 users and, with it, demand for companion supplements. GLP-1 medications suppress appetite by as much as 20%, creating nutrient gaps in protein, fiber, and micronutrients that supplement formulators are actively addressing. Brands that establish credibility in the GLP-1 companion space early are positioned to capture significant market share as oral adoption accelerates well beyond the injectable market.

This Week in Supplements: DSHEA Scope Push, Herbalife-Bioniq, and Energy Drinks in China

NutraIngredients • April 7, 2026

NutraIngredients’ weekly industry roundup this week highlights continued regulatory momentum from the FDA’s public meeting on DSHEA ingredient definitions, Herbalife’s landmark Bioniq acquisition, and emerging energy drink market shifts in China. The coverage captures a supplement sector navigating expansive regulatory opportunity and global market diversification at the same time, with DSHEA modernization now firmly on the near-term agenda for both domestic regulators and international market players watching the U.S. framework for guidance.